Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …
[HTML][HTML] Treatment of posttraumatic stress disorder: a state-of-the-art review
L Burback, S Brémault-Phillips, MJ Nijdam… - Current …, 2024 - ncbi.nlm.nih.gov
This narrative state-of-the-art review paper describes the progress in the understanding and
treatment of Posttraumatic Stress Disorder (PTSD). Over the last four decades, the scientific …
treatment of Posttraumatic Stress Disorder (PTSD). Over the last four decades, the scientific …
[HTML][HTML] Arketamine, a new rapid-acting antidepressant: a historical review and future directions
J Zhang, W Yao, K Hashimoto - Neuropharmacology, 2022 - Elsevier
The N-methyl-d-aspartate receptor (NMDAR) antagonist (R, S)-ketamine causes rapid onset
and sustained antidepressant actions in treatment-resistant patients with major depressive …
and sustained antidepressant actions in treatment-resistant patients with major depressive …
Ketamine treatment for depression: a review
This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …
The antidepressant actions of ketamine and its enantiomers
Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …
anesthetic, has shown significant promise as a medication with rapid antidepressant …
Novel glutamatergic modulators for the treatment of mood disorders: current status
The efficacy of standard antidepressants is limited for many patients with mood disorders
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …
International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators
Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset
antidepressant properties, but little is known regarding which patients are most likely to …
antidepressant properties, but little is known regarding which patients are most likely to …
Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies
AH Miller, CL Raison - Molecular Psychiatry, 2023 - nature.com
Despite advances in neuroscience, limited progress has been made in developing new and
better medications for psychiatric disorders. Available treatments in psychiatry rely on a few …
better medications for psychiatric disorders. Available treatments in psychiatry rely on a few …
Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
S Kohtala - Pharmacological Reports, 2021 - Springer
Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …
medicine as an important anesthetic with many uses. More recently, ketamine has been …
To predict, prevent, and manage post-traumatic stress disorder (PTSD): a review of pathophysiology, treatment, and biomarkers
Post-traumatic stress disorder (PTSD) can become a chronic and severely disabling
condition resulting in a reduced quality of life and increased economic burden. The disorder …
condition resulting in a reduced quality of life and increased economic burden. The disorder …